Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report

Miriam Champer; Devin Miller; Dennis Yi Shin Kuo

doi:10.1016/j.gore.2019.01.007

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report

Miriam Champer, Devin Miller, Dennis Yi Shin Kuo

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.

Original language	English (US)
Pages (from-to)	26-28
Number of pages	3
Journal	Gynecologic Oncology Reports
Volume	28
DOIs	https://doi.org/10.1016/j.gore.2019.01.007
State	Published - May 2019
Externally published	Yes

Keywords

Low-grade serous ovarian cancer
MEK-inhibitor
Targeted therapy

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.gore.2019.01.007

Cite this

@article{376e2b90ba6a4844b06d63602c6e0903,

title = "Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report",

abstract = "Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.",

keywords = "Low-grade serous ovarian cancer, MEK-inhibitor, Targeted therapy",

author = "Miriam Champer and Devin Miller and Kuo, {Dennis Yi Shin}",

year = "2019",

month = may,

doi = "10.1016/j.gore.2019.01.007",

language = "English (US)",

volume = "28",

pages = "26--28",

journal = "Gynecologic Oncology Reports",

issn = "2211-338X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation

T2 - A case report

AU - Champer, Miriam

AU - Miller, Devin

AU - Kuo, Dennis Yi Shin

PY - 2019/5

Y1 - 2019/5

N2 - Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.

AB - Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.

KW - Low-grade serous ovarian cancer

KW - MEK-inhibitor

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85061345638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061345638&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2019.01.007

DO - 10.1016/j.gore.2019.01.007

M3 - Article

AN - SCOPUS:85061345638

SN - 2211-338X

VL - 28

SP - 26

EP - 28

JO - Gynecologic Oncology Reports

JF - Gynecologic Oncology Reports

ER -

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this